Juno Therapeutics (NASDAQ:JUNO) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Wednesday, February 21st.
According to Zacks, “Juno remains on track with its pipeline and continues to pursue acquisitions and licensing agreements. The company’s deal with Celgene for global development and commercialization of immunotherapies is encouraging. Moreover, the company’s targeted, cancer immunotherapy is a highly lucrative area as these therapies have the potential to change the treatment paradigm for cancer. Shares of the company have also outperformed the industry in the last one year. However, the company suffered a huge setback with discontinuation of the development of cancer candidate, JCAR015, due to the toxicity witnessed in a phase II ROCKET study. Also, increased competition in the immunotherapy space is a matter of concern for the company. Juno’s pipeline candidates are still a few steps away from approval and hence, any setback would weigh heavily on the stock.”
A number of other research firms have also recently weighed in on JUNO. SunTrust Banks reaffirmed a “hold” rating on shares of Juno Therapeutics in a research report on Monday, January 22nd. Raymond James Financial lowered shares of Juno Therapeutics from an “outperform” rating to a “hold” rating in a report on Tuesday, January 23rd. Leerink Swann lowered shares of Juno Therapeutics from an “outperform” rating to a “market perform” rating and increased their target price for the stock from $56.00 to $87.00 in a report on Tuesday, January 23rd. Barclays lowered shares of Juno Therapeutics from an “overweight” rating to an “equal weight” rating and increased their target price for the stock from $55.00 to $87.00 in a report on Wednesday, January 24th. Finally, Standpoint Research reiterated a “hold” rating on shares of Juno Therapeutics in a report on Wednesday, January 24th. One equities research analyst has rated the stock with a sell rating, eighteen have assigned a hold rating and two have assigned a buy rating to the company’s stock. Juno Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $52.55.
In other Juno Therapeutics news, Director Richard Klausner sold 36,000 shares of the firm’s stock in a transaction on Thursday, December 21st. The shares were sold at an average price of $44.76, for a total transaction of $1,611,360.00. Following the transaction, the director now directly owns 744,392 shares of the company’s stock, valued at approximately $33,318,985.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Hans Edgar Bishop sold 270,250 shares of the firm’s stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $46.17, for a total transaction of $12,477,442.50. Following the transaction, the chief executive officer now directly owns 2,772,679 shares in the company, valued at $128,014,589.43. The disclosure for this sale can be found here. Insiders have sold a total of 473,031 shares of company stock worth $27,031,205 over the last quarter. 15.08% of the stock is owned by company insiders.
A number of institutional investors have recently modified their holdings of JUNO. Northern Trust Corp boosted its holdings in shares of Juno Therapeutics by 11.8% in the second quarter. Northern Trust Corp now owns 382,631 shares of the biopharmaceutical company’s stock valued at $11,438,000 after acquiring an additional 40,468 shares in the last quarter. Ark Investment Management LLC boosted its holdings in shares of Juno Therapeutics by 101.5% in the second quarter. Ark Investment Management LLC now owns 500,296 shares of the biopharmaceutical company’s stock valued at $14,954,000 after acquiring an additional 252,029 shares in the last quarter. Parametric Portfolio Associates LLC boosted its holdings in shares of Juno Therapeutics by 17.5% in the second quarter. Parametric Portfolio Associates LLC now owns 46,796 shares of the biopharmaceutical company’s stock valued at $1,399,000 after acquiring an additional 6,970 shares in the last quarter. Dimensional Fund Advisors LP purchased a new stake in shares of Juno Therapeutics in the second quarter valued at about $5,634,000. Finally, QS Investors LLC purchased a new stake in shares of Juno Therapeutics in the second quarter valued at about $135,000. 70.19% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: This report was originally posted by BBNS and is owned by of BBNS. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright and trademark laws. The original version of this report can be viewed at https://baseballnewssource.com/2018/03/18/juno-therapeutics-juno-upgraded-to-hold-by-zacks-investment-research/1914388.html.
Juno Therapeutics Company Profile
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Juno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.